These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23868194)

  • 21. Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity.
    Daien CI; Gailhac S; Mura T; Audo R; Combe B; Hahne M; Morel J
    Arthritis Rheumatol; 2014 Aug; 66(8):2037-46. PubMed ID: 24729478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic inflammatory pseudotumor and myasthenia gravis.
    Levin MH; Gopal PP; Galetta SL
    JAMA Ophthalmol; 2014 Mar; 132(3):359-61. PubMed ID: 24626829
    [No Abstract]   [Full Text] [Related]  

  • 23. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
    Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP
    Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab and immune deficiency: case series and review of the literature.
    Kaplan B; Kopyltsova Y; Khokhar A; Lam F; Bonagura V
    J Allergy Clin Immunol Pract; 2014; 2(5):594-600. PubMed ID: 25213054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II.
    Moberg P; Charles JF; Respicio G; Venna SS; Rooney T
    Cutis; 2010 Sep; 86(3):133-5. PubMed ID: 21049729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis.
    Rosengren S; Wei N; Kalunian KC; Kavanaugh A; Boyle DL
    Rheumatology (Oxford); 2011 Mar; 50(3):603-10. PubMed ID: 21098574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
    Lebrun C; Bourg V; Bresch S; Cohen M; Rosenthal-Allieri MA; Desnuelle C; Ticchioni M
    J Neuroimmunol; 2016 Sep; 298():79-81. PubMed ID: 27609279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.
    Marino M; Bartoccioni E; Alboini PE; Evoli A
    Ann N Y Acad Sci; 2018 Feb; 1413(1):41-48. PubMed ID: 29369382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
    Feldman RJ; Christen WG; Ahmed AR
    Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Proposal for rituximab treatment in patients with myasthenia gravis].
    Konno S
    Rinsho Shinkeigaku; 2013; 53(11):1312-4. PubMed ID: 24291971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
    Jing S; Song Y; Song J; Pang S; Quan C; Zhou L; Huang Y; Lu J; Xi J; Zhao C
    J Neuroimmunol; 2017 Oct; 311():14-21. PubMed ID: 28789841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab.
    Chan F; Swayne A; Gillis D; Walsh M; Henderson RD; McCombe PA; Wong RC; Blum S
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):955-956. PubMed ID: 30455407
    [No Abstract]   [Full Text] [Related]  

  • 33. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
    Singh N; Goyal V
    J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia.
    Eskelund CW; Nederby L; Thysen AH; Skovbo A; Roug AS; Hokland ME
    Leuk Res; 2011 Jul; 35(7):914-20. PubMed ID: 21354618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
    Yi JS; Decroos EC; Sanders DB; Weinhold KJ; Guptill JT
    Muscle Nerve; 2013 Dec; 48(6):992-3. PubMed ID: 24006142
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
    Iorio R; Damato V; Alboini PE; Evoli A
    J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
    Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
    Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered expression of miR-146a in myasthenia gravis.
    Lu J; Yan M; Wang Y; Zhang J; Yang H; Tian FF; Zhou W; Zhang N; Li J
    Neurosci Lett; 2013 Oct; 555():85-90. PubMed ID: 24036458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in dermatology.
    España A; Ornilla E; Panizo C
    Actas Dermosifiliogr; 2013 Jun; 104(5):380-92. PubMed ID: 23665436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.